ProMIS Neurosciences Inc. has announced plans to consider a reverse stock split to address its non-compliance with Nasdaq's minimum bid price requirement. The company aims to regain compliance by the extended deadline of December 29, 2025, after receiving a deficiency letter from Nasdaq. ProMIS's shares will continue to trade under the symbol "PMN" on the Nasdaq Capital Market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.